GSA Capital Partners LLP Acquires New Position in Compass Pathways PLC Sponsored ADR $CMPS

GSA Capital Partners LLP bought a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 67,879 shares of the company’s stock, valued at approximately $389,000. GSA Capital Partners LLP owned approximately 0.07% of Compass Pathways as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Nantahala Capital Management LLC increased its position in shares of Compass Pathways by 47.7% during the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares during the period. Hsbc Holdings PLC purchased a new stake in Compass Pathways during the 2nd quarter worth about $3,011,000. Schroder Investment Management Group purchased a new stake in Compass Pathways during the 2nd quarter worth about $1,525,000. Simplify Asset Management Inc. acquired a new stake in Compass Pathways in the 3rd quarter valued at about $1,662,000. Finally, 22NW LP boosted its stake in shares of Compass Pathways by 36.5% in the 2nd quarter. 22NW LP now owns 882,844 shares of the company’s stock valued at $2,472,000 after buying an additional 236,285 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Down 6.9%

Compass Pathways stock opened at $7.44 on Thursday. The company has a market capitalization of $714.39 million, a P/E ratio of -2.74 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. Compass Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The stock has a 50-day simple moving average of $6.94 and a 200-day simple moving average of $6.03.

Analysts Set New Price Targets

A number of analysts recently weighed in on CMPS shares. Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Morgan Stanley boosted their target price on shares of Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada raised their price target on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.